Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs... Show more
AKRO saw its Momentum Indicator move above the 0 level on November 14, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned positive. In of the 80 cases, the stock moved higher in the following days. The odds of a move higher are at .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AKRO advanced for three days, in of 302 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 156 cases where AKRO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 55 cases where AKRO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKRO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AKRO broke above its upper Bollinger Band on December 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
a biotechnology company, which specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases.
Industry Biotechnology